News | | More »

Active Biotech Year End Report 2023

Press Release

Active Biotech provides update on the scheduled clinical program for 2024

Press Release

Positive preclinical tasquinimod data presented at ASH 2023 now available on Active Biotech’s website

Press Release

Active Biotech announces outcome of the Company’s rights issue

Press Release

Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod

Press Release

Active Biotech's nomination committee appointed

Press Release

Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis

Press Release

Management and members of the board of directors have subscribed for shares in Active Biotech’s ongoing rights issue

Press Release

CEO Helén Tuvesson presents at Redeye Life Science Day 2023 – 23 November

Equity research and Presentations

Redeye video interview with CEO Helén Tuvesson (in Swedish)

Equity research and Presentations

Aktiespararna: “Fokus på nytt område” (in Swedish)

Equity research and Presentations

Active Biotech publishes prospectus

Press Release

Active Biotech announces a rights issue of approximately SEK 51 million

Press Release

Active Biotech presentation at Aktiespararnas “Aktiedag Lund”, October 9, 2023

Equity research and Presentations

Tasquinimod successfully completes dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort

Press Release

New preclinical data on the antifibrotic effects of tasquinimod in myelofibrosis to be presented at EHA 2023

Press Release

Safety and preliminary activity of naptumomab in combination with durvalumab presented at AACR 2023

Press Release

We Develop New Treatments for Cancer and Inflammatory Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in hematological cancers, non-infectious uveitis and in solid tumors for naptumomab in partnership with NeoTX.

Novel treatments for specialist indications

Pipeline

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Hematological malignancies
Tasquinimod Multiple myeloma*
Tasquinimod Myelofibrosis**
Inflammatory eye disorders
Laquinimod eye drops, safety and tolerability
Laquinimod eye drops, ocular biodistribution**
Solid tumors
Naptumomab Combination with docetaxel in non-small cell lung cancer
Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors
Study ongoing
* In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania
** Study preparations ongoing

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Uveitis can Lead to Severe Eye Problems Including Blindness

Laquinimod

Multiple Myeloma a Blood Cancer with Unmet Medical Need

Tasquinimod